Current Sexual Health Reports

, Volume 3, Issue 3, pp 103–106

Penile injection training

Expert’s Corner

Abstract

Injection therapy is the most effective pharmacotherapy for erectile dysfunction. Unfortunately, it has been all but forgotten by most practitioners since the advent of the oral therapy. Physicians rarely offer injection therapy as an option, despite the fact that over 6 million men have tried phosphodiesterase type 5 (PDE5) inhibitors in the United States, and 1.8 million of those men may have failed or been dissatisfied with oral therapy. Patients approached with the possibility of injection therapy fear the pain and concept of penile self-injection. Through a compassionate, supportive educational approach incorporating the physicians and their staffs, injection therapy can be a highly effective treatment for ED patients who have failed oral therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Porst H: The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996, 155:802–815.PubMedCrossRefGoogle Scholar
  2. 2.
    Mulhall JP, Jahoda AE, Cairney M, et al.: The causes of patient dropout from penile self-injection therapy for impotence. J Urol 1999, 162:1291–1294. This reference catalogues the reasons that patients drop out from injection therapy.PubMedCrossRefGoogle Scholar
  3. 3.
    Lakin MM, Montague DK, VanderBrug Medendorp S, et al.: Intracavernous injection therapy: analysis of results and complications. J Urol 1990, 143:1138–1141.PubMedGoogle Scholar
  4. 4.
    Armstrong DK, Convery A, Dinsmore WW: Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic. Int J STD AIDS 1993, 4:214–216.PubMedGoogle Scholar
  5. 5.
    Sexton WJ, Benedict JF, Jarow JP: Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urol 1998, 159:811–815.PubMedCrossRefGoogle Scholar
  6. 6.
    McCullough A, Kau E, Kaci L, Lepor H: A 12 month longitudinal study of treatment seeking behavior in 200 men after radical retropubic prostatectomy. J Urol 2003, 169(4 Suppl):S379.Google Scholar
  7. 7.
    Lebret T, Herve JM, Yonneau L, et al.: Erectile dysfunction after radical prostatectomy: value of preoperative programming of intracavernous injections. Prog Urol 1999, 9:483–488. This important paper shows that preoperative exposure to injection therapy reduces resistance to injection therapy.PubMedGoogle Scholar
  8. 8.
    Amar E, Bondil P: Is an auto-injector useful in the treatment of erectile insufficiency using intracavernous injection? Prog Urol 1997, 7:377–383.PubMedGoogle Scholar
  9. 9.
    Porst H, Buvat J, Meuleman E, et al.: Intracavernous Alprostadil Alfadex: an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 1998, 10:225–231.PubMedCrossRefGoogle Scholar
  10. 10.
    Uebel RA, Wium CA, Schmidt AC: Stability evaluation of a prostaglandin E1 saline solution packed in insulin syringes. Int J Impot Res 2001, 13:16–17.PubMedCrossRefGoogle Scholar
  11. 11.
    Bertaccini A, Gotti R, Soli M, et al.: Prostaglandin E(1)-based vasoactive cocktails in erectile dysfunction: how environmental conditions affect PGE(1) efficacy. Urol Int 2002, 68:251–254.PubMedCrossRefGoogle Scholar
  12. 12.
    Muruve N, Hosking DH: Intracorporeal phenylephrine in the treatment of priapism. J Urol 1996, 155:141–143. This paper describes effective management of postinjection priapism.PubMedCrossRefGoogle Scholar
  13. 13.
    Duffy LM, Sidi AA, Lange PH: Vasoactive intracavernous pharmacotherapy: the nursing role in teaching self-injection therapy. J Urol 1987, 138:1198–1200.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Department of UrologyNew York UniversityNew YorkUSA

Personalised recommendations